RSS Feed Print
Posted: Thursday, November 7, 2019 9:31 AM
Joined: 8/13/2019
Posts: 12

Interested in your thoughts about this new release?



Posted: Monday, November 11, 2019 11:53 PM
Joined: 2/17/2019
Posts: 347

Pretty sure that's a Lane question.


Here's a bit of the text:

About T3D-959

T3D-959 is an investigational new drug candidate and is not approved for any indication in any markets.

T3D-959 Mechanism of Action

T3D-959 activates two nuclear receptors that are central regulators of normal glucose and lipid metabolism in the brain. T3D-959 is orally-delivered as a once-a-day medicine.

T3D-959 is the first PPAR delta-activating compound to be developed for the treatment of Alzheimer’s disease (AD). Uniquely, this drug also activates PPAR gamma, albeit at 15-fold lower potency, which may provide potential additive or synergistic effects in regulating dysfunctional brain glucose energy and lipid metabolism in AD.

Both PPAR delta and PPAR gamma targets are central regulators of glucose and lipid metabolism. Agonism (activation) of both receptors maintains metabolic homeostasis in similar and different ways. PPAR delta is highly expressed throughout the central nervous system (CNS) and enriched in areas of the brain involved in energy homeostasis, e.g. the mediobasal hypothalamus.

Lane Simonian
Posted: Tuesday, November 12, 2019 7:46 PM
Joined: 12/12/2011
Posts: 4855

Many good studies being posted on these boards these days but I am slow to catch up.

This article discusses some of the potential benefits of PPAR activation for Alzheimer's disease.

One of the pathways by which PPAR activation contributes to neuroprotection is the phosphatidyinositol 3-kinase/Akt pathway, but this pathway is damaged in Alzheimer's disease.